Literature DB >> 15353042

Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.

José Ronnie Vasconcelos1, Meire I Hiyane, Cláudio R F Marinho, Carla Claser, Alexandre M V Machado, Ricardo T Gazzinelli, Oscar Bruña-Romero, José M Alvarez, Silvia B Boscardin, Mauricio M Rodrigues.   

Abstract

Protective immunity against lethal infection is developed when BALB/c or C57BL/6 mice are immunized with plasmids containing genes from the protozoan parasite Trypanosoma cruzi. However, genetic vaccination of the highly susceptible mouse strain A/Sn promoted limited survival after challenge. This observation questioned whether this type of vaccination would be appropriate for highly susceptible individuals. Here, we compared the protective efficacy and the immune response after individual or combined genetic vaccination of A/Sn mice with genes encoding trans-sialidase (TS) or the amastigote surface protein-2 (ASP-2). After challenge, a significant proportion of A/Sn mice immunized with either the asp-2 gene or simultaneously with asp-2 and ts genes, survived infection. In contrast, the vast majority of mice immunized with the ts gene or the vector alone died. Parasitological and histological studies performed in the surviving mice revealed that these mice harbored parasites; however, minimal inflammatory responses were seen in heart and striated muscle. We used this model to search for an in vitro correlation for protection. We found that protective immunity correlated with a higher secretion of interferon- by spleen cells on in vitro restimulation with ASP-2 and the presence of ASP-2-specific CD8 cells. Depletion of either CD4 or CD8 or both T-cell subpopulations prior to the challenge rendered the mice susceptible to infection demonstrating the critical contribution of both cell types in protective immunity. Our results reinforce the prophylactic potential of genetic vaccination with asp-2 and ts genes by describing protective immunity against lethal T. cruzi infection and chronic tissue pathology in a highly susceptible mouse strain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353042     DOI: 10.1089/hum.2004.15.878

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice.

Authors:  Fanny Tzelepis; Bruna C G de Alencar; Marcus L O Penido; Ricardo T Gazzinelli; Pedro M Persechini; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

3.  A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.

Authors:  Carylinda Serna; Joshua A Lara; Silas P Rodrigues; Alexandre F Marques; Igor C Almeida; Rosa A Maldonado
Journal:  Vaccine       Date:  2014-04-30       Impact factor: 3.641

4.  Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Authors:  Paula Ordonhez Rigato; Bruna C de Alencar; José Ronnie C de Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

5.  Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Authors:  O K Giddings; C S Eickhoff; T J Smith; L A Bryant; D F Hoft
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

6.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

7.  Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

Authors:  Bruna C G de Alencar; Pedro M Persechini; Filipe A Haolla; Gabriel de Oliveira; Jaline C Silverio; Joseli Lannes-Vieira; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

8.  Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection.

Authors:  Malcolm S Duthie; Maria Kahn; Arsen Zakayan; Maria White; Stuart J Kahn
Journal:  Clin Vaccine Immunol       Date:  2007-05-30

9.  Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

Authors:  O K Giddings; C S Eickhoff; N L Sullivan; D F Hoft
Journal:  Infect Immun       Date:  2010-01-04       Impact factor: 3.441

10.  The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development.

Authors:  Mauricio M Rodrigues; Ana Carolina Oliveira; Maria Bellio
Journal:  J Parasitol Res       Date:  2012-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.